pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
palladio-biosciences PRESS RELEASE ARCHIVE
Nov 17, 2020
Palladio Biosciences Announces First Patient Dosed With Lixivaptan in The ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued From Treatment With Tolvaptan Due to Liver Toxicity
Oct 20, 2020
Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting
Nov 5, 2019
Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting
Oct 11, 2019
Palladio Biosciences Appoints Marella Thorell Chief Financial Officer
Aug 8, 2019
Palladio Biosciences Appoints Alex Martin Chief Executive Officer
Apr 3, 2019
Palladio Biosciences Announces Appointment of Sanford (Sandy) Zweifach as Chairman of its Board of Directors
Jan 3, 2019
Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief Medical Officer (CMO)
Dec 18, 2018
Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 8, 2018
Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Nov 1, 2017
Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting
Oct 4, 2017
Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease
Jun 12, 2017
Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors
May 23, 2017
Palladio Biosciences Formed to Develop Transformative Medicines for Orphan Diseases of the Kidney
Mar 30, 2016
Palladio Biosciences, Inc. Named “Best in Show” at Mid-Atlantic Bio Angels 1st Pitch Philadelphia Event
